Insider updates option exercise error at Neurocrine Biosciences (NBIX)

Rhea-AI Filing Summary

Neurocrine Biosciences Chief Commercial Officer filed an amended Form 4 to correct a previously misreported stock option exercise. On November 28, 2025, the insider exercised 12,830 incentive stock options, rather than the 5,970 options originally reported. The options had an exercise price of $35.99 per share and converted into an equal number of common shares. The filing also updates the insider’s reported beneficial ownership of Neurocrine Biosciences common stock and notes that this total includes 204 shares acquired through the company’s 2018 Employee Stock Purchase Plan. The incentive stock option was granted on February 5, 2016, vested in 48 equal monthly installments beginning March 5, 2016, and was scheduled to expire on February 5, 2026.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BENEVICH ERIC

(Last) (First) (Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/28/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
12/02/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/28/2025		M(1)		12,830	A	$35.99	57,723(2)	D
Common Stock								51,753(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Incentive Stock Option	$35.99	11/28/2025		M(1)			12,830	(4)	02/05/2026	Common Stock	12,830	$0	0	D

Explanation of Responses:

1. This Form 4 is being amended to correct the reporting of the Reporting Persons November 28, 2025 transaction. Due to an administrative error, the original Form 4 inadvertently reported the exercise of 5,970 stock options. The transaction actually consisted of the exercise of 12,830 stock options.

2. Includes an aggregate of 204 shares purchased on February 28, 2025 and August 29, 2025 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.

3. This line is included solely to report the Reporting Persons corrected beneficial ownership of Common Stock in Column 5 following the November 28, 2025 transactions previously reported in the Form 4 filed on December 2, 2025.

4. The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning March 5, 2016. These options were due to expire on February 5, 2026.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	01/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the amended Form 4 for NBIX report?

The amended Form 4 reports that Neurocrine Biosciences’ Chief Commercial Officer actually exercised 12,830 incentive stock options on November 28, 2025, correcting an earlier filing that had understated the transaction.

How many Neurocrine Biosciences (NBIX) options were exercised and at what price?

The insider exercised 12,830 incentive stock options for Neurocrine Biosciences common stock at an exercise price of $35.99 per share.

What error is being corrected in this NBIX insider filing?

The original filing mistakenly reported the exercise of 5,970 stock options on November 28, 2025. The amendment clarifies that the transaction actually involved the exercise of 12,830 stock options.

Who is the insider involved in this Neurocrine Biosciences Form 4/A?

The reporting person is an officer of Neurocrine Biosciences, serving as the company’s Chief Commercial Officer, and is filing as a single reporting person.

What are the terms of the corrected Neurocrine Biosciences stock option grant?

The incentive stock option was granted on February 5, 2016, vested in 48 equal monthly installments starting March 5, 2016, and was due to expire on February 5, 2026.

Does the amended NBIX filing mention shares from an employee stock purchase plan?

Yes. The filing states that the insider’s beneficial ownership includes an aggregate of 204 shares purchased on February 28, 2025 and August 29, 2025 under the 2018 Employee Stock Purchase Plan.